Molecular Diagnostics for Cancer Markets, 2022: Exciting Technical Developments Especially in the Area of Pharmacogenics Hold the Promise of a Dynamic, Growing and Evolving World Market - ResearchAndMarkets.com
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth.
Learn all about it in this new report. It includes a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry, and now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.
Working against this dynamic market are the forces of the COVID Driven Recession. The latest numbers in this report factor in the different COVID forces and their timing, and their effect on growth.
Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
Assistance in providing specific growth and market size estimates for new technology tests is provided. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.
The report includes detailed breakouts for 18 Countries and 4 Regions; a detailed breakout for any country in the world is available. The report also includes five year market forecasts.
Molecular Diagnostics Recent Developments
Nucleix to Invest in Early-Stage Lung Cancer Dx
Invitae to Acquire Genosity for $200M
Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
Natera Revenues Grow 35 Percent
AnchorDx Closes $40M Financing Round
Exact Sciences Strategy for End-to-End Cancer Testing
Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
Singlera Genomics Closes $150M Funding for Cancer Screening
Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
Metastatic Cancer Markers Identified in Clinical WGS Study
Stitch Bio Bets on CRISPR Tech
Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
Progress, Challenges in Liquid Biopsy Reimbursement
Israeli Startup Curesponse Raises $6M
Coronavirus Pandemic Bites into European Cancer Research
Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
Combining CRISPR and Nanopore Sequencing
Liquid Biopsy Detects Cancer Early via Cell Clusters
Roche, Illumina unveil 15-year cancer diagnostic tie-up
Saga, Servier Sign Liquid Biopsy Services Deal
Home urine test could revolutionize diagnosis of prostate cancer
Cancer Gene Tests Cost-Effective for Breast Cancer Patients
Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
OncoCyte to Buy Cancer Testing Company Razor Genomics
Blood Test May Eliminate Need for Exploratory Surgery
NGS Cancer Panel Receives New York State Conditional Approval
Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb
Market Trends
Factors Driving Growth
New Diagnostics Create New Markets
New Roles for Diagnostics
Longevity and Outcomes
Expanding the Pharmaceutical Toolbox
Regulatory Retreat
Factors Limiting Growth
Falling Prices
Lower Costs
COVID Pandemic
Wellness has a Downside
Instrumentation and Automation
Instruments Key to Market Share
Bioinformatics Plays a Role
Diagnostic Technology Development
Next Generation Sequencing
Shifting Role of Diagnostics
Multiplexing and Foundation One
Pharmacogenomics Technology
Whole Genome Sequencing
Gene Editing and Gene Therapy
Market Overview
Market Participants
Academic Research Lab
Diagnostic Test Developer
Genomic Instrumentation Supplier
Cell Separation and Viewing Instrumentation Supplier.
Teck Resources Limited (Teck) today announced its unaudited first quarter results for 2024. "All outstanding major construction at our QB operation was completed in the first quarter, including the shiploader and molybdenum plant, and we marked the...
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024.
Highlights for the Quarter:
Net income available to common...